87 related articles for article (PubMed ID: 3539737)
1. Smoothing effect of a new alpha-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients.
Arends J; Willms BH
Horm Metab Res; 1986 Nov; 18(11):761-4. PubMed ID: 3539737
[TBL] [Abstract][Full Text] [Related]
2. Effect of miglitol (BAY m-1099) on fasting blood glucose in type 2 diabetes mellitus.
Sels JP; Kingma PJ; Wolffenbuttel BH; Menheere PP; Branolte JH; Nieuwenhuijzen Kruseman AC
Neth J Med; 1994 Jun; 44(6):198-201. PubMed ID: 8052342
[TBL] [Abstract][Full Text] [Related]
3. Effect of Miglitol (Bay m1099), a new alpha-glucosidase inhibitor, on glucose, insulin, C-peptide and GIP responses to an oral sucrose load in patients with post-prandial hypoglycaemic symptoms.
Renard E; Parer-Richard C; Richard JL; Jureidini S; Orsetti A; Mirouze J
Diabete Metab; 1991; 17(3):355-62. PubMed ID: 1884880
[TBL] [Abstract][Full Text] [Related]
4. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
5. A double-blind study on the efficacy and tolerance of a new alpha-glucosidase inhibitor in type-2 diabetics.
Katsilambros N; Philippides P; Toskas A; Protopapas J; Frangaki D; Marangos M; Siskoudis P; Anastasopoulou K; Xefteri H; Hillebrand I
Arzneimittelforschung; 1986 Jul; 36(7):1136-8. PubMed ID: 3533089
[TBL] [Abstract][Full Text] [Related]
6. [Alpha-glucosidase inhibitor for type 2 diabetic patients. Clinical study with miglitol].
Fehmann HC
MMW Fortschr Med; 2000 May; 142(21):55. PubMed ID: 10872296
[No Abstract] [Full Text] [Related]
7. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes: glycemic targets and oral therapies for older patients.
Lardinois CK
Geriatrics; 1998 Nov; 53(11):22-3, 27-8, 33-4 passim. PubMed ID: 9824974
[TBL] [Abstract][Full Text] [Related]
9. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
10. [Risk of complications in the diabetic patient. Postprandial blood glucose peaks as deciding factor].
MMW Fortschr Med; 2000 Jul; 142(26-27):54-5. PubMed ID: 10929491
[No Abstract] [Full Text] [Related]
11. Effect of an alpha-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics.
Joubert PH; Bam WJ; Manyane N
Eur J Clin Pharmacol; 1986; 30(2):253-5. PubMed ID: 3519244
[TBL] [Abstract][Full Text] [Related]
12. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type II diabetics.
Federlin KF; Mehlburger L; Hillebrand I; Laube H
Acta Diabetol Lat; 1987; 24(3):213-21. PubMed ID: 3687313
[TBL] [Abstract][Full Text] [Related]
13. [Effect of acarbose on postprandial increase in blood glucose. Additive acute effect of once daily administration in insulin treated diabetes].
Ledermann H; Höxter G
Fortschr Med; 1994 Nov; 112(32):467-70. PubMed ID: 7821886
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness and tolerance of long-term acarbose therapy in diabetic patients with threatened secondary failure of sulfonylurea drug treatment].
Domke A; Willms B
Med Klin (Munich); 1994 Apr; 89(4):187-92. PubMed ID: 8015532
[TBL] [Abstract][Full Text] [Related]
15. Does suppression of postprandial blood glucose excursions by the alpha-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients?
Johnson AB; Taylor R
Diabetes Care; 1996 Jun; 19(6):559-63. PubMed ID: 8725851
[TBL] [Abstract][Full Text] [Related]
16. Effects of the alpha-glucosidase inhibitor 1 desoxynojirimycin (Bay m 1099) on postprandial blood glucose, serum insulin and C-peptide levels in type II diabetic patients.
Schnack C; Röggla G; Luger A; Schernthaner G
Eur J Clin Pharmacol; 1986; 30(4):417-9. PubMed ID: 3527720
[TBL] [Abstract][Full Text] [Related]
17. Reduction of postprandial blood glucose by the alpha-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes.
Heinz G; Komjati M; Korn A; Waldhäusl W
Eur J Clin Pharmacol; 1989; 37(1):33-6. PubMed ID: 2687007
[TBL] [Abstract][Full Text] [Related]
18. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus.
Osonoi T; Saito M; Mochizuki K; Fukaya N; Muramatsu T; Inoue S; Fuchigami M; Goda T
Metabolism; 2010 Dec; 59(12):1816-22. PubMed ID: 20667563
[TBL] [Abstract][Full Text] [Related]
19. Effects of alpha-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses.
Requejo F; Uttenthal LO; Bloom SR
Diabet Med; 1990 Jul; 7(6):515-20. PubMed ID: 2163805
[TBL] [Abstract][Full Text] [Related]
20. The acute effects of glucosidase inhibition on post-meal glucose increments in insulin-dependent diabetics.
Wing J; Kalk WJ; Berzin M; Diamond TH; Griffiths RF; Smit AM; Osler CE
S Afr Med J; 1990 Mar; 77(6):286-8. PubMed ID: 2180090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
